Albert F G, Eckdahl T T, Fitzgerald D J, Anderson J N
Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907-1392, USA.
Biochemistry. 1999 Aug 3;38(31):10135-46. doi: 10.1021/bi990382p.
Distamycin and Hoechst 33258 have long served as the model compounds for biochemical, biophysical, and clinical studies of the drugs that bind in the DNA minor groove. However, the results presented in this investigation clearly show that 4,6-diamidino-2 phenylindole (DAPI) is superior to both of these drugs at negating the effects of intrinsic DNA curvature and anisotropic bendability as measured by electrophoretic and ligation analysis. In addition, DAPI was more effective than distamycin and Hoechst 33258 at inhibiting the assembly of nucleosomes onto synthetic and natural sequences that have multiple closely spaced oligo-AT sequences that serve as drug binding sites. Since these effects may be related to the biological action of the drugs, it was of interest to determine the mechanism that was responsible for the enhanced action of DAPI. The possibility that the differential drug potencies resulted from differential overall affinities of the ligands for A-tract molecules was considered, but drug binding studies suggested that this was not the case. It is also unlikely that the differential drug effects resulted from the binding of the drugs to different DNA sites since the oligo A/T binding sites for DAPI and Hoechst were centered on the same nucleotide positions as revealed by footprinting studies using exonuclease III, DNase I, and hydroxyl radical. However, the footprinting studies with DNase I did uncover a potentially important difference between the drugs. DAPI protected only the AT bp in the binding sites, while distamycin and Hoechst protected these bp as well as flanking Gs and Cs. These results permitted us to advance a preliminary model for the enhanced action DAPI. According to the model, the short length of DAPI and its absolute specificity for A/T bps with narrow minor grooves ensures that only particularly minor grooves that give rise to curvature and anisotropic bendability are occupied by the drug. Consequently, each helical deflection induced by an A-tract in the absence of the drug is countered by an opposite deflection induced by DAPI binding, thus effectively neutralizing intrinsic curvature and bending into the minor groove.
长久以来,偏端霉素和Hoechst 33258一直作为在DNA小沟中结合的药物进行生化、生物物理及临床研究的模型化合物。然而,本研究呈现的结果清楚地表明,就消除由电泳和连接分析测定的内在DNA曲率和各向异性弯曲性的影响而言,4,6-二脒基-2-苯基吲哚(DAPI)优于这两种药物。此外,在抑制核小体组装到具有多个紧密间隔的寡聚AT序列(作为药物结合位点)的合成和天然序列上时,DAPI比偏端霉素和Hoechst 33258更有效。由于这些效应可能与药物的生物学作用相关,因此确定导致DAPI增强作用的机制很有意义。曾考虑过配体对A序列分子的不同总体亲和力导致药物效力差异的可能性,但药物结合研究表明并非如此。药物效应差异也不太可能源于药物与不同DNA位点的结合,因为使用外切核酸酶III、DNase I和羟基自由基进行的足迹研究表明,DAPI和Hoechst的寡聚A/T结合位点集中在相同的核苷酸位置。然而,用DNase I进行的足迹研究确实揭示了这些药物之间一个潜在的重要差异。DAPI仅保护结合位点中的AT碱基对,而偏端霉素和Hoechst不仅保护这些碱基对,还保护侧翼的G和C。这些结果使我们能够提出一个关于DAPI增强作用的初步模型。根据该模型,DAPI的短长度及其对具有狭窄小沟的A/T碱基对的绝对特异性确保只有那些产生曲率和各向异性弯曲性的特定小沟被药物占据。因此,在没有药物的情况下由A序列引起的每个螺旋偏转都被DAPI结合引起的相反偏转所抵消,从而有效地中和内在曲率并向小沟弯曲。